| Document |
Document Title |
|
WO/2016/116563A1 |
The compound 3,3,3-trifluoro-N-((1,4-trans)-4-((3-((S)-2-methylmorpholino
)-1H- pyrazolo[3,4-d]pyrimidin-6-yl)amino)cyclohexyl)propane-1-sul
fonamidehaving the Formula (I) or a salt thereof, its opposite enantiomer, compositions comprisi...
|
|
WO/2016/113272A1 |
The present invention relates to novel azolobenzazine compounds of the formula I and the N- oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein C1 is C or CH C2 is C or CH A1 is N or C A2 ...
|
|
WO/2016/113763A1 |
A novel antileishmanial formulation containing compounds belonging to the series of (2Z,2'Z)-3,3'-(alkane-1,2-diylbis(azanediyl))bis(6-hydroxy-1
- aryl/fluorenyl hex-2-en-1-ones) or their salts thereof showing antileishmanial activity un...
|
|
WO/2016/112768A1 |
The present invention relates to a benzofuroxan oxide histone deacetylase inhibitor, and a preparation method therefor and uses thereof. The compound has a structure represented by a formula I or I', a tautomer II represented by the form...
|
|
WO/2016/110541A1 |
The present invention relates to selective Histone deacetylase 6 (HDAC6) inhibitors and compositions containing the same. Methods of treating diseases and conditions wherein inhibition of HDAC6 provides a benefit, like a cell proliferati...
|
|
WO/2016/108117A1 |
The present invention relates to a liquid topical veterinary pharmaceutical composition consisting of fipronil, permethrin at high concentration and pyriproxyfen such that it does not crystallize when it is applied to the coat of an anim...
|
|
WO/2016/108775A1 |
It has been discovered that the formulation of Nigella Sativa together with solvents had antineoplastic efficiency on cancerous cells. This formulation has been examined with DMSO and Alcoholic solvents in-vitro. The EC50 dose on Hep2 ce...
|
|
WO/2016/102931A1 |
The present invention provides an antimicrobial composition comprising at least one garlic extract and one or more of a bioflavonoid and/or an organic acid as well as the use of the same for treating or preventing bacterial, fungal or pa...
|
|
WO/2016/102431A1 |
The present invention relates to a compound of Formula (I) or tautomers thereof having pharmacological activity, processes for its preparation, pharmaceutical compositions and their use in the treatment of certain parasitic certain paras...
|
|
WO/2016/105289A1 |
It has been discovered that the formulation of Ginger (Zingiber officinale) together with solvents had antineoplastic efficiency on cancerous cells. This formulation has been examined with DMSO and Alcoholic solvents in-vitro. The EC50 d...
|
|
WO/2016/101794A1 |
The present invention relates to tizoxanide phosphate or alkane sulfonate type compounds represented by the type of Formula I, pharmaceutically acceptable salts thereof, isomers thereof, hydrates thereof or solvates thereof, and pharmace...
|
|
WO/2016/102437A1 |
The present invention relates to methods of treating demodicosis by administering an isoxazoline compound of formula (I).
|
|
WO/2016/097759A1 |
The present invention relates to compounds, in particular derivatives of the diterpenoids sempervirol and 7‐keto‐sempervirol, and their use in therapy, including in pharmaceutical compositions and combinations, especially in the trea...
|
|
WO/2016/100893A1 |
Methods and compositions for activating TORC1 aggregate formation in a fungi or a parasite, wherein TORC1 aggregate formation inhibits growth of the fungi or parasite. TORC1 aggregate formation may be activated using small molecules or o...
|
|
WO/2016/094659A1 |
A compound of Formula II, or a salt, ester, solvate, hydrate or prodrug thereof: where: X1 is a branched or unbranched C1-10 alkyl, (CH2)s-NH-(CH2)t, (CH2)s-0-(CH2)t, or (CH2)S-C(NH2)- (CH2)v-NH-(CH2)t,where s, t and v are each, independ...
|
|
WO/2016/087184A1 |
The present invention relates to detergents or cleaning agents, containing at least one protease and at least one organic compound of formula (I), said compound acting as a protease inhibitor and thus being a suitable enzyme stabilizer, ...
|
|
WO/2016/087182A1 |
The present invention relates to detergents and cleaning agents containing at least one protease and at least one organic compound of the formula (I) which acts as a protease inhibitor and therefore is a suitable enzyme stabilizer, and t...
|
|
WO/2016/083827A1 |
The present invention relates to pharmaceutical composition for intranasal or pulmonary delivery, wherein the composition comprises an artemisinin derivative and optionally one or more pharmaceutically acceptable excipients. The pharmace...
|
|
WO/2016/084944A1 |
Provided is a physiologically active peptide which comprises a partial amino acid sequence of enolase originated from Plasmodium falciparum and which has a molecular structure that meets the standards set for the production of GMP. A pep...
|
|
WO/2016/081592A1 |
Novel antimicrobial compositions comprise at least a form of a fosfomycin (or suitable analogs, or derivatives thereof), and at least one sulfonamide (or suitable analogs, or derivatives thereof), and/or at least one diaminopyridine (or ...
|
|
WO/2016/072939A1 |
The present disclosure discusses formulations comprising hydrophobic antimicrobial agents and uses thereof. More precisely, the present disclosure refers to a composition comprising a hydrophobic antimicrobial agent and a cyclodextrin.
|
|
WO/2016/066574A1 |
Disclosed are compounds of formula (I) which possess anthelminthic properties wherein the structural elements have the meaning as indicated in the description. Further disclosed are such compounds for the control, treatment and/or preven...
|
|
WO/2016/069578A1 |
The present invention relate to bromodomain inhibitor compounds, pharmaceutical compositions comprising the bromodomain inhibitor compounds and methods of treating a disorder responsive to fee modulation of a BET family polypeptide using...
|
|
WO/2016/063963A1 |
The present invention addresses the problems of providing an inhibitor for the hatching of hematophagous pest eggs, a pesticidal composition for hematophagous pests and a pesticidal and ovicidal method for hematophagous pests, wherein tr...
|
|
WO/2016/063848A1 |
Provided is an antimalarial that effectively acts against malaria caused by Plasmodium infection, particularly chloroquine-resistant and/or artemisinin-resistant Plasmodium infection. Further provided is an antimalarial with which the ef...
|
|
WO/2016/059911A1 |
The present invention addresses the problem of providing a malaria vaccine exhibiting a higher protective effect than that of conventional malaria vaccines. The present invention was perfected due to the discovery that, after a recombina...
|
|
WO/2016/055836A1 |
The present technology relates to a new heterologous expression process for the kinesin repeat, using specific primers which make it possible to construct a recombinant antigen with 7.5 repeats of K39 associated with a degenerated repeat...
|
|
WO/2016/054745A1 |
Novel methods and uses for modulating immune responses are provided. The methods and uses involve the use of a TIFA activator such heptose-1,7- 5 bisphosphate or an analogue or derivative thereof. The methods may be used to activate, inh...
|
|
WO/2016/055607A1 |
The compound 3-(benzo[d]thiazol-5-yl)-5-(methylamino)-1-(2,2,2-trifluoroe
thyl)-1H- pyrazole-4-carboxamide, having the Formula (I): or a salt thereof, compositions comprising the compound, its use in the treatment or prevention of Chagas...
|
|
WO/2016/055611A1 |
The present invention relates to a method for eliciting in a subject an immune response against a pathogenic organism and to a method for the treatment or prevention of an infection of a subject by a pathogenic organism.
|
|
WO/2016/052247A1 |
A pyrimidinone compound represented by formula (1) has excellent efficacy in controlling harmful arthropods. (In the formula: A1 represents a nitrogen atom or CR4; as for A2 and A3, A2 represents a nitrogen atom and A3 represents CR3b, o...
|
|
WO/2016/046419A1 |
The present invention relates to novel immunostimulatory molecules which are derived from the intestinal protozoan Entamoeba histolytica.The compounds have been found to be useful for enhancing and/or inducing an immune response in a sub...
|
|
WO/2016/042154A1 |
A parasiticide formulation is provided. The formulation is not toxic to fish when administered by intraperitoneal injection. The formulation is a homogeneous non-aqueous parasiticide solution. The formulation comprises: (a) a hydrophilic...
|
|
WO/2016/039444A1 |
The purpose of the present invention is to disclose and provide an agricultural and horticultural insecticide that is novel in terms of factors such as the occurrence of pests resistant to existing chemicals, since damage due to pests an...
|
|
WO/2016/040555A1 |
Kits and systems are described for the treatment of malaria in relevant areas of the world. Kits comprise various malaria treating drugs, malaria testing, and hydration components for treatment of the main malarial infections, wherein th...
|
|
WO/2016/038045A1 |
The present invention relates to pyrazolopyridine derivatives, which are useful as medicaments, pharmaceutical compositions comprising one or more of the pyrazolopyridine derivatives, and the use of one or more of the pyrazolopyridine de...
|
|
WO/2016/037240A1 |
The present invention provides an immunogenic composition comprising a charged antigen electrostatically associated with a Toll-Like Receptor (TLR) targeting moiety. The TLR targeting moiety comprises a TLR-2 agonist covalently attached ...
|
|
WO/2016/038223A1 |
The present invention concerns compounds of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diasteroisomers thereof formual (I): wherein at least one of W, X and Y is selected from the group consisting o...
|
|
WO/2016/038238A1 |
The invention relates to the use of ester derivatives of pyrazole, preferably proton-ionizable derivatives in neutral form or in the form of salts (pyrazolates), as drugs and, more particularly, for preventing and/or for treating disease...
|
|
WO/2016/036954A1 |
The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R1, R3, R4, R5, and each Re have any of the values defi...
|
|
WO/2016/034559A1 |
The present invention relates to a method for preparing marmycin A and analogues thereof, to novel marmycin A analogues, and also to the use of these compounds as an organelle marker and in pharmacy, in particular as antibiotics, antican...
|
|
WO/2016/037026A1 |
Cyclohexylethyl substituted diaza- and triaza-tricyclic compounds, such as e.g. 5-(2-(cyclohexyl)ethyl)-5H-imidazo[5,1-a]isoindole, 1-Cyclohexyl-2-[4,6,10-triazatricyclo[6.4.0.0^[2,6]]dodeca-1
(8),2,4,9,11-pentaen-7-yl]ethan-1-ol derivat...
|
|
WO/2016/033635A1 |
The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in ...
|
|
WO/2016/033341A1 |
The present invention relates to a new compound of formula (I) wherein the variables have the meaning as indicated in the claims; or an enantiomer or salt thereof. The compounds of formula (I) are useful in the control of parasites, in p...
|
|
WO/2016/027790A1 |
In the production of agricultural and horticultural crops, damage by pests and the like is still significant, and development of a novel pesticide for agricultural and horticultural use is desired because of the emergence of pests that a...
|
|
WO/2016/027264A1 |
The present disclosure provides liposomes comprising a lipid membrane enclosing an intraliposomal compartment, said liposome: (i) encapsulates in the intraliposomal compartment an iron complex comprising an iron moiety and a macromolecul...
|
|
WO/2016/024587A1 |
The present invention provides a compound represented by formula (I), a salt thereof, or the like. (In the formula, A1 and A2 each independently represents a nitrogen atom or the like; B1, B2, B3, and B4 each independently represents a c...
|
|
WO/2016/024168A1 |
A semiochemical composition comprising a sea lice copepodits attachment inhibiting semiochemical comprising a synthesized palmitoleic acid, salts thereof, derivatives thereof, isomers thereof and/or structural analogs thereof and/or mixt...
|
|
WO/2016/024240A1 |
A peptide-polymer conjugate is provided for use in treating malaria infections, and in particular terminal or drug resistant malaria infections. The conjugate is formed from a polymer to which a peptide having activity against a malaria ...
|
|
WO/2016/020544A1 |
The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile- salt hydrolase (BSH)enzyme, a bacterium able to s...
|
